Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOST-ABLE trial of oral semaglutide in Parkinson's disease
jRCT2051230090Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in Parkinson's disease (PD) (3 arms), sponsored by Japan Agency for Medical Research and Development. Started Nov 2023; status: completed.
02
Drugs
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2051230090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230090.